Membranous Nephropathy

Area of Science:

• Nephrology
• Immunology
• Glomerular Diseases

Background:

• Membranous nephropathy (MN) is a glomerular disease with primary (autoimmune) and secondary forms.
• Primary MN involves autoantibodies against podocyte antigens, primarily phospholipase A2 receptor (PLA2R), leading to immune complex formation and complement activation.
• The disease often presents as nephrotic syndrome (NS), with a significant risk of progression to end-stage kidney disease (ESKD) if untreated.

Purpose of the Study:

• To summarize the pathophysiology, clinical presentation, and treatment of primary membranous nephropathy (PMN).
• To highlight the challenges in achieving stable remission and the need for comprehensive management strategies.

Main Methods:

• Review of existing literature on the pathogenesis and clinical management of PMN.
• Analysis of treatment outcomes, including the efficacy of immunosuppressive agents like rituximab, corticosteroids, cyclophosphamide, and calcineurin inhibitors.
• Discussion of supportive therapies including antiproteinuric, anti-lipemic, and anticoagulant medications.

Main Results:

• Primary MN is characterized by immune complex deposition in the glomeruli due to autoantibodies targeting podocyte antigens (e.g., PLA2R).
• Nephrotic syndrome is a common clinical manifestation, with a substantial risk of progression to ESKD (35-40% in 10 years) without treatment.
• Current immunosuppressive therapies offer variable success, with fewer than 50% of patients achieving complete and stable remission; relapses are common.
• Supportive treatments are crucial for managing proteinuria, hyperlipidemia, and thrombotic risk.

Conclusions:

• Primary membranous nephropathy is a complex autoimmune condition requiring multifaceted treatment approaches.
• Achieving sustained remission remains a challenge, underscoring the need for ongoing research into more effective therapies.
• Comprehensive management involving immunosuppression and supportive care is essential to prevent complications and slow disease progression towards ESKD.